Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can HIV status change TB treatment success? a zambian study investigates

NCT ID NCT07798167

Knowledge-focused Sponsor: Centre for Infectious Disease Research in Zambia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

Researchers in Zambia are tracking 374 adults with pulmonary tuberculosis to compare treatment outcomes between those with and without HIV. The study follows participants through the end of TB treatment to see who achieves a successful outcome. The goal is to inform TB treatment policies in Africa and build a research network for future studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could guide TB treatment policies in Africa and create a platform for future TB studies in Zambia.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may not apply to other regions or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

374 people

The number who actually took part.

Started

Sep 2022

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

553

Ages

15 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Be ≥15 years of age * Clinically diagnosed pulmonary TB and initiated/to be initiated on anti-TB treatment, as determined by medical providers through standard of care, on the basis of either. * Microbiologically confirmed pulmonary TB based on sputum or other respiratory samples with either Exclusion Criteria: * Have plans to follow-up for TB care at a site distant from the enrollment site, imminent plans to move from his/her current area of residence, or plans to return to a distant area of residence, which would interfere with the participant's ability to complete all study visits (through the 12-month post-treatment visit). * 1\. Received \>1 week of TB treatment within the prior 30 days, excluding TB preventive therapy * 3\. Have substantial cognitive impairment that in the opinion of the site investigator or designee may interfere with the ability to give reliable informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary tuberculosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

To access the individual-level effects of HIV and antiretroviral therapy

Contacts and locations

Locations

  • Chawama and Kanyama General Hospitals

    Lusaka, Lusaka Province, 10101, Zambia

More trials for these conditions

Other studies related to the condition(s) this trial covers.